IASLC TTLC 2022 | LDS1 as a potential target in SCLC

Small cell lung cancer (SCLC) is an aggressive form of lung cancer and immunotherapy as a treatment option remains limited due to downregulation of major histocompatibility complex (MHC) class I molecules. Triparna Sen, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, describes ongoing research relating to lysine-specific histone demethylase 1A (LSD1), which is found to be upregulated in cancer cells. In vitro and animal models have shown that inhibition of LDS1 upregulates MHC class I expression and antigen presentation, improving the anti-tumor response. This interview took place at the 2022 Targeted Therapies of Lung Cancer Meeting (TTLC 2022).